Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of LVRNA012 in Adults in China
NCT05549206Unknown
- Sponsor
- AIM Vaccine Co., Ltd.
- Start
- Apr 2023
- Primary completion
- Apr 2023
- Modality
- Antisense DNA, Vaccines & Immunotherapeutics, Small Interfering RNA (siRNA)
01
Overview
Randomised, double-blind trial of LVRNA012 in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by AIM Vaccine Co., Ltd. Primary endpoints: SARS-CoV-2 Novel coronavirus S protein antibody (IgG) level, Levels of neutralizing antibodies of SARS-CoV-2 (Omicron BA.2, BA.4, BA.5 and Delta strains) true virus and 1 more. Status: unknown.
02
Drugs
LVRNA012
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05549206.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05549206.